Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Cullinan Therapeutics, Inc.

NASDAQ: CGEM · Life Sciences · 8 alerts · CIK 1789972

Share price
$9.50Close, Nov 16
Market cap
$617M
Shares outstanding
64.92MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Cullinan Therapeutics, Inc. filings on SEC EDGAR ↗

7:21 AM ET 8-K
Clinical Trial Data

Cullinan Therapeutics Clinical Trial Data

Cullinan Therapeutics announced positive interim Phase 1b/2a clinical data for velinotamig in patients with refractory systemic lupus erythematosus (SLE). The data showed that 8 of 9 evaluable patients achieved clinically meaningful reductions in disease activity, with 4 of 7 patients with high baseline proteinuria achieving a complete renal response. The therapy demonstrated a favorable safety profile with no Grade 3 or higher cytokine release syndrome or neurotoxicity.

Counterparty
Chongqing Genrix Biopharmaceutical Co., Ltd.
9:18 AM ET 8-K
Clinical Trial Data

Cullinan Therapeutics Clinical Trial Data

Cullinan Therapeutics released updated Phase 1 dose escalation data for CLN-049 in patients with relapsed or refractory AML and MDS, showing an ORR of 45% at the 12 µg/kg dose level. The company also announced that these results, along with data for velinotamig, will be presented at the 68th ASH Annual Meeting in December 2026. The data demonstrated that a two step-up dosing regimen improved safety by reducing the incidence and severity of cytokine release syndrome.

7:30 AM ET 8-K
Clinical Trial Data

Cullinan Therapeutics Clinical Trial Data

Cullinan Therapeutics and Taiho announced positive results from the Phase 3 REZILIENT3 trial evaluating zipalertinib plus chemotherapy in first-line EGFR exon 20 insertion mutation-positive NSCLC. The trial met its primary endpoint, showing a statistically significant median progression-free survival of 14.5 months compared to 8.5 months for chemotherapy alone (HR 0.50).

Counterparty
Taiho Pharmaceutical Co., Ltd.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.